Obatala Sciences

Obatala Sciences aims to bring diversity to the research field with their contract research services and products offered to industry and academia. The company caters to a wide range of clients, including major pharmaceutical companies, US government entities, contract research organizations, non-profit organizations, and academic research laboratories. Founded in 2017 and based in the United States, Obatala Sciences specializes in areas such as obesity, diabetes, energy metabolism, musculoskeletal system biology, and wound healing. Their unique offering, ObaCell™, serves as an exceptional fat tissue model for disease modeling and drug screening. The company's expertise spans proteomics, genomics, functionality, and adipokine secretion, and they also have the capability to form white or brown fat tissue upon request. The latest funding round for the company was a $3.00M Series A investment on 13 October 2022, led by prominent investors including Elevate Capital, être Venture Capital, Benson Capital Partners, Ochsner Lafayette General, and The Hackett Group. Obatala Sciences' commitment to driving diversity in research and their innovative solutions in the biotechnology and healthcare industries make them an attractive prospect for potential investors seeking to support impactful and forward-thinking ventures.